Routine Urine Drug Screening in Palliative Care-A Call for Evidence Before Implementation

Urine drug screening (UDS) has become an increasingly prominent component of opioid stewardship in palliative care, driven by guideline recommendations, state, and institutional requirements. Despite this adoption, the evidence base supporting routine UDS in palliative populations has not been subjected to rigorous critical scrutiny.

To evaluate the evidentiary foundation for routine UDS in palliative care and cancer pain populations, examining safety benefit, cost burden, ethical implications, guideline consistency, documented harms, and the risk of racially disparate application.

Narrative review and critical analysis conducted in accordance with the SANRA framework. PubMed/MEDLINE was searched through May 2025 using structured search terms across three domains: UDT terminology, cancer/palliative care, and opioid therapy. Clinical practice guidelines (NCCN, ASCO, CDC) were reviewed systematically. Studies were included if they addressed UDT utilization, outcomes, or policy in adult patients with cancer or receiving palliative care on opioid therapy.

No published study demonstrates that routine UDS in palliative or cancer pain populations improves patient safety outcomes, including overdose prevention, reduction in diversion, improvement in pain control, or survival. Aberrancy rates reported across studies range from 15% to 54% in palliative cohorts but represent surveillance findings, not safety endpoints. UDS rarely changes opioid management, and there are documented risks of financial toxicity, patient stigmatization, inappropriate care termination, and racially disparate application. Self-report likelihood ratio analysis demonstrates that UDS adds meaningful diagnostic information only when patients deny use-the scenario most ethically charged within a therapeutic relationship. Major guidelines recommend UDS while acknowledging that the evidence is at the lowest tier and that the practice can cause patient harm.

Routine UDS in palliative care lacks demonstrated benefit and carries documented harm. Guideline bodies, policymakers, institutional leaders, and clinicians should restrict recommendations to clinically individualized situations pending prospective evidence of patient safety benefit. Future research requirements and an equity-informed framework for selective, indicated screening are proposed.